Fitch C D, Chan R L, Chevli R
Antimicrob Agents Chemother. 1979 Feb;15(2):258-62. doi: 10.1128/AAC.15.2.258.
The process of mefloquine accumulation was studied in mouse erythrocytes infected with either Plasmodium berghei CS (chloroquine susceptible) or P. berghei CR (chloroquine resistant). In both cases, mefloquine was accumulated by a saturable process with an apparent dissociation constant of 2.5 x 10(-6) M and an apparent maximal capacity of 700 mumol per kg of erythrocyte pellet; uninfected mouse erythrocytes accumulated more than half as much mefloquine as infected erythrocytes. The process of accumulation was not stimulated by providing glucose as a substrate, and it was not inhibited in infected erythrocytes by azide, iodoacetate, or incubation at 2 degrees C. Although mefloquine was accumulated more effectively than chloroquine by uninfected erythrocytes and by erythrocytes infected with P. berghei CR, competition between chloroquine and mefloquine was observed, raising the possibility that the same process of accumulation serves both drugs. Chloroquine competitively inhibits mefloquine accumulation, with an apparent inhibitor constant of 1.7 x 10(-3) M, and mefloquine competitively inhibits chloroquine accumulation, with an apparent inhibitor constant of 2 x 10(-6) M. The same process of accumulation and the same group of receptors could serve both drugs if mefloquine has greater access than chloroquine to the receptors. Regardless of whether the same process serves both drugs, undiminished accumulation by erythrocytes infected with P. berghei CR provides an explanation for the superiority of mefloquine in treating chloroquine-resistant malaria.
在感染伯氏疟原虫CS株(对氯喹敏感)或伯氏疟原虫CR株(对氯喹耐药)的小鼠红细胞中研究了甲氟喹的蓄积过程。在这两种情况下,甲氟喹均通过一个可饱和过程蓄积,其表观解离常数为2.5×10⁻⁶ M,表观最大容量为每千克红细胞沉淀700 μmol;未感染的小鼠红细胞蓄积的甲氟喹量超过感染红细胞的一半。提供葡萄糖作为底物并不能刺激蓄积过程,叠氮化物、碘乙酸盐或在2℃孵育也不会抑制感染红细胞中的蓄积过程。尽管未感染的红细胞以及感染伯氏疟原虫CR株的红细胞对甲氟喹的蓄积比氯喹更有效,但观察到氯喹和甲氟喹之间存在竞争,这增加了两种药物通过相同蓄积过程蓄积的可能性。氯喹竞争性抑制甲氟喹的蓄积,其表观抑制常数为1.7×10⁻³ M,甲氟喹竞争性抑制氯喹的蓄积,其表观抑制常数为2×10⁻⁶ M。如果甲氟喹比氯喹更容易与受体结合,那么相同的蓄积过程和同一组受体可能对两种药物都适用。无论两种药物是否通过相同过程蓄积,感染伯氏疟原虫CR株的红细胞中甲氟喹蓄积未减少,这为甲氟喹治疗耐氯喹疟疾的优越性提供了解释。